Zai Lab Limited ZLAB
At closeNov 6, 2026, 4:05 PM EST
After hours · Nov 6, 4:05 PM ET
- YTD
- +44.44%
- 1 year
- +10.06%
- Market cap
- 3.16B
- Revenue (ttm)
- 449.61M
- Profit margin
- -41.86%
- EPS (ttm)
- -1.80
- Shares out
- 124.15M
- Forward P/E
- -12.16
- YTD return
- +44.44%
- 1-year return
- +10.06%
- Volume
- 1.89M
- Avg volume
- 1.09M
- Open
- 23.55
- Previous close
- 22.60
- Day's range
- 23.35 – 25.99
- 52-week range
- 15.96 – 27.50
- Beta
- 0.72
- Analysts
- Strong Buy
- Price target
- 33.48 (+31.4%)
- Earnings date
- Feb 25, 2027
5D +3.47 (+15.77%)
Key statistics
- Enterprise value
- 2.20B
- PEG ratio
- 0.00
- Price / sales
- 7.04
- Price / book
- 3.94
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -3.30%
- Free cash flow
- -83.96M
- Total cash
- 617.52M
- Total debt
- 254.58M
- Return on equity
- -26.91%
- Short % of float
- 8.00%
- 50-day average
- 24.64
- 200-day average
- 21.05
Analyst view
Consensus: strong buy
- Target (low)
- 24.25
- Target (mean)
- 33.48
- Target (high)
- 50.00
- Strong buy2
- Buy8
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.63721.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.63721 | — | — | — |
| Nov 5, 2026 | Sep 30, 2026 | -0.59177 | -0.41 | +0.18 | +30.72% |
| Aug 6, 2026 | Jun 30, 2026 | -0.67939 | -0.46 | +0.22 | +32.29% |
| May 7, 2026 | Mar 31, 2026 | -0.52616 | -0.46 | +0.07 | +12.57% |
| Feb 26, 2026 | Dec 31, 2025 | -0.44 | -0.46 | -0.02 | -4.55% |
| Nov 6, 2025 | Sep 30, 2025 | -0.28 | -0.33 | -0.05 | -17.86% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 7, 2026 | Citigroup | main | Buy | Buy |
| May 8, 2026 | Citigroup | main | Buy | Buy |
| Mar 18, 2026 | JP Morgan | main | Overweight | Overweight |
| Feb 27, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Feb 5, 2026 | JP Morgan | main | Overweight | Overweight |
| Jan 7, 2026 | UBS | init | — | Buy |
About Zai Lab Limited
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- China
- Website
- zailaboratory.com
News
Zai Lab Q3 Earnings Call Highlights 
Zai Lab Limited (ZLAB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates 
Zai Lab To Present Updated Data From Phase 1b/2 Trial Of Zocilurtatug Pelitecan Showing Clinically Meaningful, Durable Anti-Tumor Responses In Patients With Previously Treated Advanced Extrapulmonary Neuroendocrine Carcinomas At The North American Neuroendocrine Tumor Society Symposium 
Zai Lab Q3 2026 Earnings Call Transcript 
Zai Lab Q3 EPS $(0.04) Beats $(0.07) Estimate, Sales $108.208M Beat $105.825M Estimate 
Zai Lab Announces Third Quarter 2026 Financial Results and Recent Corporate Updates 
Zai Lab Announces Phase 1b Zoci Plus Atezolizumab Trial Delivers 81.8% Response Rate In First-Line Extensive-Stage Small Cell Lung Cancer, Advances Toward Phase 3 
Zai Lab Reports Q2 2026 Results: Full Earnings Call Transcript 
The Insider Report: The Leaders Have Taken Off 
Limoneira Posts Downbeat Q3 Results, Joins Cooper Companies, Navan And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Your note
Sign in to keep a note on ZLAB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AMADO RAFAEL | President | Sale | Apr 5, 2026 | 57,022 |
| DIEKMAN JOHN DAVID | Director | Stock Award(Grant) | Jun 16, 2026 | 122,140 |
| DU YING SAMANTHA | Chief Executive Officer | Conversion of Exercise of derivative security | Jul 1, 2026 | 1,221,400 |
| GAYNOR RICHARD BRIAN M.D. | Director | Purchase | Jun 30, 2026 | 80,737 |
| LEUNG NISA BERNICE WING-YU | Director | Stock Award(Grant) | Jun 16, 2026 | 96,297 |
| MOULDER LEON OLIVER JR. | Director | Stock Award(Grant) | Jun 16, 2026 | 94,973 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 5.78% | 6,574,032 | 167.51M | Jun 29, 2026 |
| TCG Crossover Management, LLC | 5.39% | 6,137,627 | 156.39M | Jun 29, 2026 |
| RA Capital Management, L.P. | 5.05% | 5,743,533 | 146.35M | Jun 29, 2026 |
| Adar1 Capital Management, LLC | 2.96% | 3,369,034 | 85.84M | Jun 29, 2026 |
| FMR, LLC | 2.47% | 2,815,214 | 71.73M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 2.03% | 2,315,480 | 59.00M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| BARON SELECT FUNDS-Baron Emerging Markets Fund | 1.20% | 1,370,904 | 34.93M | Jun 29, 2026 |
| iShares Trust-iShares Biotechnology ETF | 0.65% | 740,494 | 18.87M | Sep 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.29% | 331,780 | 8.45M | Sep 29, 2026 |
| abrdn World Healthcare Fund | 0.27% | 311,294 | 7.93M | Jun 29, 2026 |
| Tema ETF Trust-Tema Oncology ETF | 0.14% | 161,278 | 4.11M | Aug 30, 2026 |
| ALPS ETF TRUST-ALPS Medical Breakthroughs ETF | 0.12% | 134,267 | 3.42M | Aug 30, 2026 |